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Abstract: Prioritisation methodologies are often used for identifying those pharmaceuticals 22 
that pose the greatest risk to the natural environment and to focus laboratory testing or 23 
environmental monitoring towards pharmaceuticals of greatest concern. Risk-based 24 
prioritisation approaches, employing models to derive exposure concentrations, are 25 
commonly used but the reliability of these models is unclear. The present study evaluated 26 
the accuracy of exposure models commonly used for pharmaceutical prioritisation. Targeted 27 
monitoring was conducted for 95 pharmaceuticals in the Rivers Foss and Ouse in the City of 28 
York, UK. Predicted environmental concentration (PEC) ranges were estimated based on 29 
localised prescription, hydrological data, reported metabolism and wastewater treatment 30 
plant (WwTP) removal rates, and were compared to measured environmental 31 
concentrations (MECs). For the River Foss, PECs, obtained using highest metabolism and 32 
lowest WwTP removal, were similar to MECs. In contrast, this trend was not observed for 33 
the River Ouse, possibly due to pharmaceutical inputs beyond our modelling. 34 
Pharmaceuticals were ranked by risk based on either MECs or PECs. With two exceptions 35 
(dextromethorphan and diphenhydramine), risk ranking based on both MECs and PECs 36 
produced similar results in the River Foss. Overall, these findings indicate that PECs may well 37 
be appropriate for prioritisation of pharmaceuticals in the environment when robust and 38 
local data on the system of interest are available and reflective of most source inputs to the 39 
system. 40 
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INTRODUCTION 46 
There is increasing concern over the presence and potential effects of pharmaceuticals in 47 
the natural environment. The ubiquitous presence of pharmaceuticals in aquatic systems is 48 
well-established [1,2]. Pharmaceuticals are designed to induce a biological response at 49 
nanomolar concentrations, raising questions regarding the risk for unintended sub-lethal 50 
chronic effects in exposed non-target organisms [3]. Of the approximately 1500 51 
pharmaceuticals currently in use in the UK alone, acute ecotoxicity data are available for 52 
only a small proportion of these and chronic data are even more scarce [4]. Additionally, 53 
little is known about the environmental fate of most pharmaceuticals [5]. Few have 54 
undergone extensive fate testing such as quantifying half-lives in environmental matrices, 55 
partitioning to sludge, soils, or sediment and uptake into terrestrial and aquatic organisms. 56 
Therefore substantial knowledge gaps exist that need to be filled before we can fully 57 
understand the effects of pharmaceuticals in the natural environment. To fill these gaps 58 
experimentally, however, would require substantial effort in terms of time and cost. 59 
Prioritisation methodologies provide a useful tool for identifying which of the thousands 60 
of pharmaceuticals in use have the greatest potential to cause unintended effects in non-61 
target organisms and which therefore should be experimentally tested in terms of their fate 62 
and effects [6].  Several prioritisation approaches have been proposed for pharmaceuticals. 63 
For example, hazard-based approaches have involved the prediction of persistence, 64 
bioaccumulation, and toxicity of a pharmaceutical and these have then been used to 65 
develop an overall hazard score. Compounds with the highest scores are considered to have 66 
the highest priority [7]. Risk-based approaches have involved the estimation or 67 
measurement of pharmaceutical concentrations in environmental media and the 68 
comparison of these concentrations with an effect endpoint, for example predicted no-69 
effect concentrations derived from acute or chronic ecotoxicity data [8 W10] or predictions 70 
[11], plasma therapeutic concentrations [12], acceptable daily intakes for humans [13] or a 71 
combination of these [4]. Risk-based methods have been identified as preferable due to the 72 
consideration of effects and environmental occurrence, ruling out the possibility of 73 
prioritising compounds that have little chance of accumulating in the environment at 74 
ecologically relevant concentrations [6,13]. 75 
All risk-based approaches require an assessment of the concentration of pharmaceuticals 76 
in the environment. Real environmental data are desirable, however, monitoring data are 77 
generally lacking for a wide range of pharmaceuticals. Moreover, when monitoring data are 78 
available, the relevance of the data is often questionable due to sampling designs that do 79 
not consider seasonal biases, hydrologic conditions or spatiotemporal fluctuations [14]. As a 80 
result, comparing absolute measured concentrations of pharmaceuticals for prioritisation 81 
has been questioned [15]. Furthermore, sufficiently sensitive analytical methods, suitable 82 
for complex environmental matrices, or isotopically labelled standards necessary for 83 
accurate quantitation are not yet available for the majority of pharmaceuticals in use, 84 
making determination of pharmaceuticals in environmental matrices challenging [9,11].  85 
Consequently, many risk-based prioritisation methods have employed exposure 86 
prediction models or algorithms to derive predicted environmental concentrations (PECs) in 87 
order to prioritise pharmaceuticals that have no monitoring data and/or to provide 88 
conservative estimates of environmental concentrations [16]. PECs are typically derived 89 
based on data on pharmaceutical usage, degree of metabolism in humans, removal in 90 
wastewater treatment plants (WwTP) and environmental dilution. The method most 91 
commonly used is based on the approach recommended in the European Medicines Agency  92 
(EMEA) guidelines for assessment of the risk of human pharmaceuticals in the environment 93 
[6,9,11,17 W23]. Default parameters (e.g. for dilution of wastewater) proposed by the EMEA 94 
guidance are regularly used in these prioritisation exercises, regardless of their suitability 95 
[6,10,19,20]. The use of site-specific data when performing these calculations for 96 
prioritisation is a rarity [21].  97 
The impact of using PECs for prioritisation has not been explored, although several 98 
authors have explored how well PECs compare to measured environmental concentrations 99 
(MECs) [1,2,16,24 W29]. These comparisons have provided varied results, with some studies 100 
showing that PECs adequately represent MECs [24 W28], while others suggest the differences 101 
are too great to be useful, or that PECs generally under represent MECs [1,16,29]; in 102 
addition, these comparative studies concentrate on pharmaceuticals that have been 103 
identified as being of concern, or of high usage and generally focus on fewer than 10 104 
compounds [28], limiting the relevance of their conclusions across the broader spectrum of 105 
physico-chemically diverse pharmaceuticals known to be present in the environment 106 
globally.  107 
 Usually the determination of PEC relevancy is reliant on determining a PEC/MEC ratio. 108 
The acceptability of the PEC depends on how close this ratio is to 1 [29], however the 109 
acceptable range varies between studies [28]. This poses a problem when trying to assess 110 
the relevance of results across studies because the derivation of these ranges is subjective 111 
and dependent on the motive of the study (e.g. prioritisation or risk assessment).  112 
In the present study, we evaluate PEC models for use in prioritisation by comparing 113 
modelled and monitoring data from a comprehensive set of 95 pharmaceuticals derived 114 
from a wide range of therapeutic classes with different modes of action, an extensive range 115 
of chemical and physical properties, high and low usage, as well as select pharmaceuticals 116 
not thought to be prescribed in the UK.  The city of York (population of 227 000) was chosen 117 
as the study system due to the availability of local prescription data, a well-defined and 118 
accessible hydrological system (i.e. two rivers that pass through the city), and numerous 119 
access points to the rivers via bridges, which enables a detailed characterisation of 120 
pharmaceutical concentrations throughout the city. The prioritisation approach used to 121 
compare PECs and MECs was based on the Fish Plasma Model (FPM) [12]. Studies of this 122 
nature that assess a large range of compounds (95), are an important check on ensuring 123 
that priority compounds identified, using common modelling approaches, are comparable 124 
to those using environmental data representative of key seasonal, locational, water 125 
treatment and hydrological differences.  126 
METHODS 127 
Study site and sampling 128 
We collected and analysed river water samples from eight sites along the Rivers Ouse 129 
and Foss in the City of York in the UK where flow conditions were below the long term mean 130 
flow and near the Q50 (i.e where flow is equal or exceeded 50% of the time) in February 131 
2015 (Figure 1)[30]. Site locations were chosen based on ease of access and their position in 132 
relation to WwTP outfalls discharging into these river systems (Supplemental Data, Table 133 
S1). Two WwTPs serve the city of York that impact the sampling network. There is a third 134 
WwTP; however, it is downstream of the city and sampling points (not included in Figure 1). 135 
The first of these two WwTPs (WwTP A)  serves a population of 27 900, employs 136 
conventional activated sludge (CAS) as secondary treatment and nitrifying filters as a 137 
tertiary treatment option, and the second (WwTP B) serves a population of 18 600 and uses 138 
trickling filter technology as secondary treatment paired with biological aerated filtration for 139 
tertiary treatment.  140 
At each site, three 1-L samples were collected at points distributed equidistant across the 141 
width of the river channel and homogenised into a single 1 L composite sample. Three 10-142 
mL aliquots were taken from the composite sample and filtered through 0.7 µm glass 143 
microfiber (GF/F) disposable filters (Whatman Inc.). To ensure that filtration and field 144 
handling of samples did not result in cross-contamination, high-performance liquid 145 
chromatography (HPLC)-grade water was also filtered and prepared in the field identically to 146 
river samples (i.e. a field blank) three times during the sampling. Samples were frozen 147 
directly in the field using dry ice and transported to the U.S. Geological Survey (USGS) 148 
National Water Quality Laboratory in Denver Colorado, USA. They arrived four days later 149 
and were immediately thawed and analysed.  150 
Analytical Methods 151 
Samples were analysed using a direct injection (100 µL) high-performance liquid 152 
chromatography/tandem mass spectrometry with an electrospray ionization source (LC-ESI-153 
MS/MS)  method for the determination of 110 pharmaceuticals, pharmaceutical degradates, 154 
and wastewater indicator compounds [31]. Of the 110 compounds, 95 pharmaceuticals 155 
were targeted in the present study with method detections limits (MDL) as defined by the 156 
US Environmental Protection Agency (USEPA) [32] down to 0.45 ng/L (Table 1). 157 
Instrumentation included an Agilent 6410 triple quadrupole MS/MS system coupled with an 158 
Agilent 1200 Series HPLC. Mobile phases were HPLC-grade water modified with 1M formic 159 
acid and 1M ammonium formate (A) and 100% HPLC grade methanol (B). Chromatography 160 
gradient and conditions are detailed in Supplemental Data, Table S2. Quantification and 161 
identification was achieved by external calibration with known standards for each of the 162 
pharmaceuticals and completed using Agilent Mass Hunter software in accordance with the 163 
USGS methodology described in Furlong et al. [31]. The MS/MS was operated in multiple 164 
reaction monitoring (MRM) mode, where two MRM transitions and correct retention times 165 
were required for ion qualification, while quantification was based on the major transition 166 
(Supplemental Data, Table S3). Additionally, ion ratios between the major and secondary 167 
transitions were required to fall within a compound-specific range determined from the 168 
corresponding analytical standard [31]. Concentrations reported in the present study are 169 
the median of three aliquots taken from each site. 170 
Statistical analysis and quality control. The limit of quantification (LOQ) was established 171 
as 2 to 5 times the MDL where the probability of incorrectly reporting the presence of an 172 
analyte is less than 1% when concentrations are equal to or greater than the LOQ [33]. 173 
Concentrations greater than the LOQ were fully quantitative while concentrations detected 174 
between the LOQ and MDL were considered semi-quantitative estimates. To enable the 175 
consideration of as many pharmaceuticals as possible, both quantitative and semi-176 
quantitative data were used in subsequent data analyses.  177 
Quality control samples were analysed to (1) assess matrix recovery efficiency and 178 
identify the presence of matrix interferences that could induce ion suppression or 179 
enhancement [34], and (2) identify any blank contamination from sampling and analysis. For 180 
recovery assessment, an environmental sample was amended with the pharmaceuticals of 181 
interest (matrix spike) to a concentration of 400 ng/L. The aforementioned field blank 182 
samples were analysed to identify any potential contributions of pharmaceuticals during 183 
sample collection, laboratory processing and analysis. In addition to the field blank and 184 
matrix spike samples, analogous laboratory spike and blank samples, using high purity HPLC-185 
grade water, also were analysed with each batch of environmental samples. 186 
 187 
PEC Modelling  188 
The calculation of PECs for the 95 pharmaceuticals was based on Equation 1.  189 
WA? ĐŽŶƐƵŵƉƚŝŽŶ ?&ĞǆĐƌĞƚĂ ?൫ ?-tǁdWƌĞŵŽǀĂů൯ŝŶŚĂďŝƚĂŶƚƐ 踀 ttŝŶŚĂď 踀 ĚŝůƵƚŝŽŶ                                                                                               (1) 190 
Where the numerator represents the river input rate (ng per day): consumption = 191 
amount used per day (ng/day); Fexcreta is the fraction of pharmaceutical excreted unchanged 192 
by patients; and WwTP removal is the fraction of a pharmaceutical removed by water 193 
treatment.  The denominator is the river flushing rate where: inhabitants = population 194 
served by the WwTP; WWinhab = amount of wastewater generated (L/day·person), which has 195 
a default value of 200; dilution was based on site-specific conditions in each river.  196 
Pharmaceutical usage was generated from localised prescription data released monthly 197 
by the National Health Service for January 2015 [35]. Relevant medical practices were 198 
selected by postal code (Supplemental Data, Table S4). The Fexcreta term was obtained from 199 
either the peer-reviewed literature or online databases such as Drugbank, MedSafe and 200 
RXmed, as well as publicly available pharmaceutical data sheets released by government 201 
organisations such as MedSafe New Zealand or the Food and Drug Agency (Supplemental 202 
Data, Table S5). When a pharmaceutical was metabolised to conjugated metabolites (e.g. 203 
glucuronide or sulfato-conjugates), the portion released as a conjugate was added to the 204 
unchanged parent excretion estimate. These metabolites can undergo reactions during 205 
water treatment such as cleavage and thus be converted back into their parent compounds, 206 
increasing the parent pharmaceutical load in wastewater effluent [36]. Estimates of 207 
unchanged pharmaceutical excretion varied across sources; this led to a range of possible 208 
unchanged excretion estimates, which were used to calculate a PEC range. For ophthalmic 209 
and topical preparations, metabolism was assumed to be zero and therefore the Fexcreta was 210 
set to 1 [19]. 211 
Wastewater treatment removal was considered in two ways due to the limited 212 
availability of removal estimates for all pharmaceuticals in the present study [37]. Firstly, 213 
removal values from the literature were collected and, similarly to Fexcreta estimates, varied 214 
substantially (Supplemental Data, Table S5). The range of possible WwTP removal estimates 215 
were used to calculate a possible PEC range. Secondly, data gaps were filled using the 216 
h^W ?ƐW/^Ƶŝƚe software STPWIN program [38], similarly to a recent prioritisation exercise 217 
in Asia [20].  218 
Evaluation of PECs 219 
Separate PEC ranges were calculated for pharmaceuticals for both the River Foss and 220 
River Ouse. The PEC range incorporated a river-specific dilution factor reflecting hydrological 221 
conditions on the day of sampling. The lowest Fexcreta and highest WwTP removal values 222 
found in the literature were paired to give a minimum PEC, while the maximum was derived 223 
using the highest Fexcreta and lowest WwTP removal found in the literature. A PEC (worst 224 
case) was also calculated which only considered site-specific dilution (ie. Fexcreta = 1, WwTP 225 
removal = 0).   226 
Prioritisation Approach 227 
The fish plasma model (FPM) approach [12,39], which has been used in previous 228 
prioritisation exercises [6], was selected as the method used for prioritisation. 229 
Bioconcentration factors (BCFs) for neutral and ionisable compounds were estimated 230 
according to the approach of Fu et al. [40] (Supplemental Data, Equations S1-S5) and used 231 
to determine fish plasma concentrations (FPCs) based on either PECs or MECs .  FPCs were 232 
then compared to human plasma therapeutic concentrations (indicated by Cmax) using 233 
Equation 2 to determine the risk quotient (RQ).  The Kow and Cmax for all compounds were 234 
collected from the MaPPFAST database complied by Berninger et al. [41]. 235 
ZYA?W 踀B&ŵĂǆ                                                                                                                                         (2) 236 
RQs are ranked from highest to lowest risk, where a larger RQ indicates a greater 237 
potential risk. Using this approach, we obtained two ranking lists, one based on FPCs 238 
obtained from PECs, the other using FPCs obtained from MECs. 239 
RESULTS AND DISCUSSION 240 
Pharmaceutical Occurrence  241 
No pharmaceuticals were detected in the field blanks collected indicating that sample 242 
collection, handling, and analysis did not result in measurable contamination of the water 243 
samples (i.e. protocols did not generate false positives for the present study).  Calculated 244 
recoveries from quality control matrix spike samples generally fell within 60-120% and were 245 
considered acceptable [42]. Recoveries failing to meet these criteria are identified and 246 
subsequently interpreted with caution. Reported values were not corrected for percentage 247 
of analyte recovered in environmental matrix spikes [43]. The median matrix recovery was 248 
88% while the 25 and 75 percentiles were 81 and 160% respectively; this distribution 249 
suggests that some matrix enhancement of compound recoveries is occurring.  250 
Of the 95 pharmaceuticals surveyed, 25 compounds were detected and quantified 251 
(Figure 2) in the eight water samples collected from the York network. A further 19 252 
pharmaceuticals were detected, however only qualitative or semi-quantitative assessment 253 
was appropriate due to either quantification limits (11) or unacceptable matrix 254 
interferences (7) (Table 1). Of the 25 pharmaceuticals quantified, 10 have not been 255 
previously identified in the UK aquatic environment ƚŽ ƚŚĞ ĂƵƚŚŽƌƐ ? ŬŶŽǁůĞĚŐĞ: acyclovir, 256 
diphenhydramine, glyburide, hydrocodone, lidocaine, methocarbamol, oseltamivir, 257 
sitagliptin, triamterene and loratadine. The remaining 15 pharmaceuticals detected were 258 
consistent with the ranges reported previously in the literature (Table 1). Ten 259 
pharmaceuticals included in the analysis are not prescribed in the UK and were not detected 260 
in any samples.  Median and maximum detected concentrations, along with detection 261 
frequency and matrix recoveries for all target analytes are reported in Table 1. 262 
The concentrations and number of detections between the Rivers Ouse and Foss varied 263 
(Fig. 2) with concentrations of six pharmaceuticals in the River Foss being significantly higher 264 
ƚŚĂŶ ŝŶ ƚŚĞ KƵƐĞ  ?^ƚƵĚĞŶƚ ?Ɛ d-test, p < 0.05). A greater number of and more consistent 265 
detections occurred in the River Foss, (Fig. 2) which has both a lower dilution factor and the 266 
corresponding WwTP (WwTP B) provides less sophisticated water treatment (trickling filter) 267 
compared to the treatment used by WwTP A discharging to the River Ouse (conventional 268 
activated sludge). 269 
Evaluation of Modelled Concentrations with Monitoring Data 270 
The EMEA PEC model describes an annual average concentration for the region the 271 
consumption data cover; in general, usage data from the whole of a country is averaged to 272 
give a single PEC [4]. Evaluating this approach with localised, temporally limited samples 273 
would introduce a source of potential error as it has been shown that seasonal usage is 274 
important for some pharmaceuticals and that demographics in a specific area may differ 275 
substantially from the national average [25,26]. To reduce these potential biases, local 276 
usage data, corresponding to time of sampling, was used. In addition, site-specific dilution 277 
factors were incorporated to avoid the use of EMEA [23] default dilution factors (i.e. 10). 278 
The WWinhab term could not be refined to actual discharge because both WwTPs are highly 279 
variable and discharge measurements were not available for the sampling dates. This 280 
permits a focus on other factors that could be affecting the suitability of PECs such as WwTP 281 
removal and metabolism. 282 
Overall PEC Performance 283 
Many pharmaceuticals targeted were not detected in the monitoring campaign, however 284 
based on their PECs, this was not unexpected. To assess the overall performance of the 285 
PECs, a semi-quantitative approach was taken.  Each of the 77 pharmaceuticals for which a 286 
PEC could be calculated were sorted into one of four possible categories (Figure 3). 287 
Pharmaceuticals that were expected to be detected in the monitoring campaign (i.e. PEC 288 
greater than the corresponding analytical MDL) were sorted into either detected or not 289 
detected categories. Similarly, pharmaceuticals not expected to be detected (i.e. PEC less 290 
than the respective analytical MDL) were sorted into detected and not detected categories. 291 
Overall in the semi-quantitative analysis, the PECs in the two rivers performed well with 79% 292 
and 86% of predictions correctly confirmed in the River Foss and Ouse, respectively, by the 293 
monitoring data.  294 
The large difference in dilution between the two rivers, factors of 17.8 and 540 for the 295 
Foss and Ouse respectively, led to larger PECs in the River Foss and therefore a higher 296 
number of expected detections. A larger proportion of expected detections were not 297 
identified in our monitoring campaign in the Foss in comparison to the Ouse; it could be that 298 
pharmaceuticals were missed by our sampling effort, however our results indicate that 299 
pharmaceutical concentrations are stable throughout the River Foss over an 8-hour period 300 
(Figure 2), which diminishes the likelihood of missing a detection. Conversely, the 301 
metabolism or WwTP removal selected from the literature may have produced PECs larger 302 
than real-world concentrations. The number of unexpected but detected pharmaceuticals is 303 
greater in the River Ouse, despite corrections for upstream contributions detected at site 4, 304 
(Figure 2). The River Ouse could be subject to a greater number of sources not reflected in 305 
our usage estimate in contrast to the more rural River Foss. Sources of pharmaceuticals 306 
beyond the scope of localised prescription data exist within the city include, for example, a 307 
substantial tourism industry and two post-secondary institutions. Recent studies have 308 
demonstrated the impact of post-secondary institutions [44] and music festivals [45] on 309 
MECs, and it is likely that MECs in the Ouse are influenced by demographic factors not 310 
inclusive of localised prescription-based usage estimates. 311 
Impact of Metabolism and WwTP Removal Uncertainty on PECs 312 
Underestimated PECs: A breakdown of how each pharmaceutical PEC performed in 313 
comparison to the MEC is shown for the River Foss (Figure 4) and the River Ouse (Figure 5). 314 
While the overall semi-quantitative performance of PECs in the River Ouse was slightly 315 
better than the Foss, these results were not repeated when quantitative data were 316 
compared. In the Foss and the Ouse, 38% and 78% respectively, of the MEC ranges were 317 
entirely greater than the corresponding PEC range.  This drops to 12% and 44% respectively 318 
when the PEC (worst case) is considered. The PEC (worst case) does not include metabolism 319 
or WwTP removal, only dilution, and when this PEC still falls below the MEC it indicates a 320 
problem with the consumption estimate. The analytical matrix spike recoveries indicated 321 
that matrix enhancement is occurring, which could affect the comparisons with PECs. To 322 
investigate, each compound with a MEC range greater than the PEC range was theoretically 323 
corrected based on the compound specific matrix recovery. All of the theoretically corrected 324 
MEC ranges were still greater than the corresponding PEC ranges in the River Ouse and Foss 325 
with one exception, erythromycin, where the MEC range corresponded with the top of the 326 
PEC range in the River Foss. Therefore we do not expect our results to be significantly 327 
altered by the distribution in matrix recoveries.  328 
In the River Foss, three pharmaceuticals (dextromethorphan, diphenhydramine and 329 
pseudoephedrine) had greater MECs than PEC (worst case) estimates and are all available 330 
over-the-counter (OTC). This consumption pathway was not considered in our consumption 331 
estimate as we were unable to access data on sales of OTC medicines. As a result, PECs for 332 
these pharmaceuticals should be systematically underestimated [2,24,27].  This was not 333 
reflected for all OTC pharmaceuticals, similarly to a recent study in Canada [28]. This 334 
highlights the need for a new approach to incorporate OTC consumption into WwTP 335 
pharmaceutical loadings [4,27]. The results from the River Ouse (Figure 5) are more 336 
complicated, a mixture of both OTC and prescription-only pharmaceuticals had MECs which 337 
were greater than the PEC (worst case) estimates. This supports our semi-quantitative 338 
findings where a problem exists with the consumption estimate and is likely a result of the 339 
specific demographics impacting pharmaceutical loads for the River Ouse.  340 
PEC ranges: The PEC range is large for many of the pharmaceuticals. For instance the 341 
paracetamol PEC range covers over 4 orders of magnitude (Figure 4). This large uncertainty 342 
is a result of the extensive variability in experimental WwTP removal and Fexcreta estimates 343 
obtained from the literature. In both rivers, the majority of PEC ranges vary by at least 2 344 
orders of magnitude, which could be important from both a risk assessment and 345 
prioritisation perspective. The large PEC range does mean that, in general, the MEC range 346 
did correspond with predictions in the River Foss (Figure 4). The MEC range is typically near 347 
the top of the PEC range, where the smallest WwTP removal was paired with the highest 348 
unchanged excretion found in the literature. This finding has two implications: firstly, 349 
choosing the worst-case fate parameters to estimate PECs is likely the best approach to 350 
avoid underestimations of PECs, which is in agreement with PEC approaches in the literature 351 
[46]; secondly, anything short of an exhaustive literature review could lead to 352 
underestimated PECs in the majority of cases shown in Figures 4 & 5. This is because the 353 
PEC ranges determined herein are the result of an exhaustive literature review; in a larger 354 
scale prioritisation exercise the time resources required to thoroughly check each 355 
compound would be impractical and the process itself highly subjective. This could lead 356 
authors to different conclusions about the resulting risks and priority compounds as it is a 357 
single value computed for the PEC, not a range, which is a substantial flaw not often 358 
considered when the fate data used in a PEC are collected in this manner. 359 
Our results indicate that consideration of metabolism and WwTP removal is essential 360 
when calculating PECs because PEC (worst case) is a large overestimate of actual 361 
concentrations in the majority of cases (Figure 4), also shown by others [6,10,22]. In the 362 
River Foss, prescription pharmaceuticals are described well using the PEC approach. This is 363 
in sharp contrast in the River Ouse, where multiple consumption sources are likely affecting 364 
concentrations of the pharmaceuticals in the environment, making it impossible to evaluate 365 
the effect of the fate parameters with the current dataset. Further monitoring that 366 
incorporates sampling WwTP influents and effluents to compute actual removals will be 367 
critical to assessing PECs relative to MECs. In addition, the uncertainty in measured 368 
concentrations can be limited by incorporating time-averaged composite samples 369 
representative of the average conditions [14]. Further work which includes a seasonal 370 
monitoring campaign is suggested to quantify the seasonal variability and magnitude of 371 
influence that tourism and post-secondary institutions have on MECs in addition to serving 372 
as a check of the findings from the present initial scoping study.  373 
 374 
 375 
Implications for prioritisation 376 
Risk ranking order is important as it dictates which pharmaceuticals are of highest risk 377 
and thus, most likely to receive further costly investigations into effects and occurrence [4]. 378 
Therefore we evaluated the similarities and differences between risk rankings obtained 379 
based on MECs and rankings based on PECs for the River Foss (Figure 6A) and River Ouse 380 
(Figure 6B). In the River Foss, while there was some variability in the ranking position of 381 
individual compounds, generally, the rankings based on MECs and PECs followed a similar 382 
trend. Compounds identified as highest risk based on MECs also were identified as highest 383 
risk based on PECs and those ranked as lower risk based on MECs also ranked as lower risk 384 
using PECs (Figure 6A). The exceptions were dextromethorphan and diphenhydramine 385 
where the rank position was much higher based on MECs than based on PECs. This degree 386 
of similarity was not observed in the River Ouse (Figure 6B). Eight of the MEC ranks are 387 
higher risk than their PEC rank counterparts, which visually, is a more variable but gentler 388 
rise (Figure 6B).  This indicates that the degree in which PECs were underestimated in the 389 
River Ouse affects prioritisation ranking order trends.  390 
CONCLUSIONS 391 
We have presented real-world monitoring data for a comprehensive set of 95 392 
pharmaceuticals in two rivers that run through the city of York, UK. During a snapshot 393 
sampling where flow conditions were below the long-term mean and near the Q50 in 394 
February 2015, 25 pharmaceuticals were quantified (i.e. detected), 10 of which had not 395 
been previously measured in the UK aquatic environment. Site-specific PEC ranges varied up 396 
to four orders of magnitude due to the variability in metabolism and WwTP removal values 397 
found in the literature. The largest unchanged excretion paired with the lowest WwTP 398 
removal approach provided the greatest comparability to measured concentrations. Some 399 
of the observed differences between MECs and PECs might be explained by complex social 400 
demographics, such as tourism or post-secondary institutions, which are suspected of 401 
influencing wastewater loading estimates. When PECs and MECs were used to prioritise the 402 
detected pharmaceuticals based on risk, generally the two approaches provided similar 403 
ranking outcomes for well-defined systems such as the River Foss, but were less comparable 404 
in the more complicated system, the River Ouse. The findings for the Foss, in particular, 405 
provide some confidence in the use of PECs in prioritisation exercises for pharmaceuticals.  406 
SUPPLEMENTAL DATA 407 
Table S1 National grid references of sampling site locations 408 
Tables S2-S3 Analytical operating conditions. 409 
Tables S4-S5 PEC parameters.  410 
Equations S1-S5 Bioconcentration factor equations. 411 
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 602 
Figure 1. Locations of the 8 sampling sites around the city of York, UK. A and B represent the WwTPs 603 
that service the city. Grab samples were collected in February 2015.604 
  605 
Table 1. Occurrence data for the 8 water samples collected during February 2015 from the sampling network with matrix recovery and method detection 606 
limits for each of the 95 pharmaceuticals, pharmaceutical degradates and wastewater indicators targeted. 607 
Pharmaceutical Source or use MDL (ng/L) 
Detection 
Frequency 
% 
Max 
(ng/L) 
Median 
(ng/L) 
Matrix 
recovery % 
(median) 
Detected in 
the UK (ng/L) 
10-Hydroxy-
amitriptyline Degradate of amitriptyline 1.7 0 ND ND 110  
Abacavir Antiviral 4.1 0 ND ND 73  
Acyclovira Antiviral 4.4 13 7.9 7.9 60  
Albuterola ȕ-adrenergic receptor  1.2 0 ND ND 180 38 ± 4702 e 
Alprazolam Benzodiazepine  4.3 0 ND ND 75  
Amitriptyline Antidepressant 19 25 <MDL <MDL 250 1.0 ± 72f,g 
Amphetamine Psychostimulant 4.1 0 ND ND 76 1.1 -4f 
Antipyrineb Analgesic 58 20 <MDL <MDL 87  
Atenolol Beta blocker 2.7 13 25 25 97 <1 ± 530e 
Benztropineb,c Anticholinergic 7.9 0 ND ND 300  
Bupropion Antidepressant 3.6 0 ND ND 86  
Carbamazepine Anticonvulsant 0.84 38 27 22 80 <0.5 ± 52e,h 
Carisoprodol Muscle relaxant 2.5 0 ND ND 81  
Chlorpheniraminea,c Antihistamine 0.94 13 2.4 2.4 220  
Cimetidinec H2-receptor antagonist 5.6 38 <MDL <MDL 100 <0.5 ± 202e 
Citalopramc Antidepressant 1.3 50 37 14 170 53i 
Clonidine Antihypertensive 30 0 ND ND 87  
Dehydronifedipine Nifedepine metabolite 4.9 0 ND ND 78  
Desmethyl-diltiazemc Degradate of diltiazem 2.5 25 48 44 210  
Desvenlafaxine Antidepressant, venlafaxine 
metabolite  3.8 88 85 16 87 7.3 ± 290
 i,j
 
 Pharmaceutical Source or use MDL (ng/L) 
Detection 
Frequency 
% 
Max 
(ng/L) 
Median 
(ng/L) 
Matrix 
recovery % 
(median) 
Detected in 
the UK (ng/L) 
Dextromethorphana,c Cough suppressant 1.6 25 6.7 6.0 140  
Diazepam Benzodiazepine  0.45 63 1.3 1.0 81 0.6± 1.1f,g 
Diltiazemc Calcium channel blocker 5.1 63 44 9.1 180 <1 ± 49e 
Diphenhydraminea Antihistamine 2.9 25 6.0 5.6 100  
Erythromycinc Macrolide antibiotic 27 25 180 170 250 <0.5 ± 1000k,l 
Ezetimibec Cholesterol-reducing agent 13 25 <MDL <MDL 160  
Fadrozoleb Aromatase inhibitor 1.5 0 ND ND 92  
Fenofibrate H2-receptor antagonist 1.3 0 ND ND 100  
Fexofenadine Antihistamine 4.0 100 130 18 90 64j 
Fluconazolea Antifungal 36 0 ND ND 76  
Fluoxetinec Antidepressant 5.4 0 ND ND 360 6.2 ± 34f,m 
Fluticasonec Synthetic corticosteroid 0.92 63 <MDL <MDL 86  
Glipizide Antidiabetic 17 0 ND ND 82  
Glyburide Antidiabetic 0.79 88 3.1 <MDL 81  
Hydrocodone Opioid, codeine metabolite 2.1 25 39 34 110  
Hydrocortisone Natural glucocorticoid hormone 29 0 ND ND 77  
Hydroxyzine Glucocorticoid hormone 1.5 0 ND ND 110  
Iminostilbene Carbamazepine degradate 73 0 ND ND 98  
Ketoconazolec Antifungal 56 0 ND ND 430  
Lamivudinec Antiretroviral 3.2 0 ND ND 160  
Lidocainea Topical anesthetic 3.1 75 9.6 8.9 84  
Loperamide c Antidiarrheal 5.7 0 ND ND 420  
Loratadinea Antihistamine 1.4 88 8.5 1.5 120  
Pharmaceutical Source or use MDL (ng/L) Detection Max Median Matrix Detected in 
 Frequency 
% 
(ng/L) (ng/L) recovery % 
(median) 
the UK (ng/L) 
Lorazepam Benzodiazepine (anxiolytic) 58 0 ND ND 84  
Meprobamate Anxiolytic 17 0 ND ND 74  
Metaxaloneb Muscle relaxant 7.8 0 ND ND 80  
Metformin Antidiabetic 6.6 100 1300 630 120 2300j 
Methadonec Synthetic opioid 3.8 0 ND ND 200 10 ± 18g 
Methocarbamol Muscle relaxant 4.4 25 10 8.7 81  
Methotrexate Chemotherapy agent 11 0 ND ND 76 <6.3n 
Metoprololc Beta-blocker 14 0 ND ND 86 <0.5 ± 12e 
Morphine Analgesic (opioid) 2.8 30 21 19 84 0.6 ± 36f,g 
Nadolol Beta-blocker 16 0 ND ND 85  
Nevirapinec Antiretroviral 3.0 25 <MDL <MDL 81  
Nizatidinec Acid inhibitor (ulcers) 9.5 0 ND ND 240  
Noreistherone Oral contraceptive 
component 2.2 13 <MDL <MDL 85 <10 ± 17
s
 
Nordiazepam Benzodiazepine, diazepam 
metabolite 21 0 ND ND 82 0.1 ± 6.8f 
Norverapamilc Verapamil metabolite 1.7 0 ND ND 400  
Omeprazolec Proton pump inhibitor 2.8 0 ND ND 260  
Oseltamivir Antiviral 2.9 38 3.6 <MDL 85  
Oxazepam Benzodiazepine (anxiolytic) 28 0 ND ND 81 0.9 ± 21f 
Oxycodone Opioid analgesic 5.0 0 ND ND 90 0.4 ± 7.1f,g 
Paracetamola Analgesic 3.6 63 1000 260 88 52 ± 2400d,e 
Paroxetinec Antidepressant 4.1 0 ND ND 300  
Penciclovirc Antiviral 8.1 0 ND ND 160  
Pharmaceutical Source or use MDL (ng/L) 
Detection 
Frequency 
% 
Max 
(ng/L) 
Median 
(ng/L) 
Matrix 
recovery % 
(median) 
Detected in 
the UK (ng/L) 
 Pentoxyfyllinec Cardiovascular drug 4.7 10 <MDL <MDL 86  
Phenazopyridineb Urinary tract analgesic 2.7 0 ND ND 84  
Phendimetrazineb Appetite suppressant 16 0 ND ND 86  
Phenytoin Antiepileptic  94 0 ND ND 78  
Piperonyl butoxideb Pesticide, lice treatment 1.5 13 2.8 2.8 87  
Prednisolone Synthetic corticosteroid, prednisone metabolite 75 0 ND ND 91  
Prednisone Synthetic corticosteroid 84 0 ND ND 120  
Promethazinea,c Antihistamine 10 50 <MDL <MDL 190  
Propoxyphene Opioid analgesic 3.4 0 ND ND 140 9 -680k,o 
Propranolol Beta blocker 13 50 27 18 110 3.9- 220k,p 
Pseudoephedrinea Decongestant 5.5 13 8.5 8.0 81 12 ± 17g 
Quininea,c Antimalarial, flavouring agent 16 50 41 23 140  
Raloxifene Selective estrogen receptor 
modulator  4.9 0 ND ND 420  
Ranitidinea Acid inhibitor (ulcers) 38 100 180 72 100 <3 ± 73e,h,q 
Sertralinec Antidepressant 3.3 0 ND ND 300  
Sitagliptin Antihyperglycemic 20 25 36 20 81  
Sulfadimethoxineb Sulfonamide antibiotic 33 0 ND ND 83  
Sulfamethizoleb Sulfonamide antibiotic 21 0 ND ND 82  
Sulfamethoxazole Sulfonamide antibiotic 13 38 <MDL <MDL 80 1.8 ± 8e,j 
Tamoxifenc Cancer treatment  11 0 ND ND 3300 <10 ± 210k,o 
Temazepam Benzodiazepine (hypnotic) 9.2 25 <MDL <MDL 81 1.4 ± 78 
Theophylline Diuretic 8.3 0 ND ND 75  
Pharmaceutical Source or use MDL (ng/L) 
Detection 
Frequency 
% 
Max 
(ng/L) 
Median 
(ng/L) 
Matrix 
recovery % 
(median) 
Detected in 
the UK (ng/L) 
Thiabendazoleb Fungicide 0.82 0 ND ND 83  
 Tiotropiumc Bronchodilator 8.6 0 ND ND 220  
Tramadol Opioid analgesic 3.0 50 77 49 90 3.0 ± 7700e,f 
Triamterene Diuretic 2.6 25 4.2 <MDL 80  
Trimethoprim Antibiotic 3.8 75 31 22 86 <1.5 ± 180e,r 
Venlafaxine Antidepressant 0.90 38 15 12 95 1.1 ± 85 
Verapamilc Calcium channel blocker 3.1 0 ND ND 550  
Warfarin Anticoagulant 3.0 25 <MDL <MDL 84  
% = percentage; ng/L = nanograms per litre; MDL = Method detection limit; ND = Not detected 
a Available over-the-counter in the UK 
b Not prescribed in York, UK in January 2015 
cAPI reported as estimate  due to being only qualitatively confirmed (<MDL) or environmental matrix recovery quality assurance criteria (60-
120%) according to Furlong et al. [42], reported values are not corrected for percentage of analyte recovered in environmental matrix spikes 
according to Wershaw et al. [43] 
dBound & Volvoulis, 2006 [47] 
eKasprzyk-Hordern et al., 2008 [48] 
fBaker & Kasprzyk-Hordern, 2013 [49] 
gBaker & Kasprzyk-Hordern, 2011 [50] 
hKasprzyk-Hordern et al., 2009 [51] 
iEvans et al., 2015 [52] 
jPetrie et al., 2015 [53] 
kAshton et al., 2004 [54] 
lHilton et al., 2003 [55] 
mRoberts & Bersuder, 2006 [56] 
nAherne et al., 1990 [57] 
oRoberts & Thomas, 2006 [58] 
pZhang & Zhou, 2007 [59] 
qKasprzyk-Hordern et al., 2007 [60] 
rBoxall et al., 2011 [61] 
sAherne et al., 1985 [62] 
  
 
Figure 2. A heat map of the mean pharmaceutical concentration at each of the 8 sampling sites along 
the Rivers Ouse and Foss. Numbers refer to the specific sampling sites listed in Figure 1. Significant 
differences in concentrations between the River Ouse and Foss were found for the 6 
pharmaceuticals that were detected frequently enŽƵŐŚƚŽĐŽŵƉƵƚĞĂƐƚƵĚĞŶƚ ?Ɛƚ-test, * indicates a p 
A? ? ? ? ? ?
 
 
Figure 3. A semi-quantitative analysis of PEC performance in the rivers based on the monitoring 
campaign results. A compound is expected to be detected when the PEC is greater than the 
respective analytical method detection limit.  
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Figure 4. PEC range and MEC range for compounds quantified in the River Foss. The worst case PEC 
is also plotted (open circles) where Fexcreta = 1 and WwTP removal = 0. The MEC range is based on the 
results from sampling sites 1-3 (Figure 1). 
 
 
Figure 5. PEC range and MEC range for compounds quantified in the River Ouse. The worst case PEC 
is also plotted (open circles) where Fexcreta = 1 and WwTP removal = 0.The MEC range is based on the 
results from sites 5-7 (Figure 1) and corrected for the upstream contributions.  
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